AU2020351301C1 - New compounds - Google Patents

New compounds

Info

Publication number
AU2020351301C1
AU2020351301C1 AU2020351301A AU2020351301A AU2020351301C1 AU 2020351301 C1 AU2020351301 C1 AU 2020351301C1 AU 2020351301 A AU2020351301 A AU 2020351301A AU 2020351301 A AU2020351301 A AU 2020351301A AU 2020351301 C1 AU2020351301 C1 AU 2020351301C1
Authority
AU
Australia
Prior art keywords
methyl
imidazol
urea
phenyl
isobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020351301A
Other languages
English (en)
Other versions
AU2020351301B2 (en
AU2020351301A1 (en
Inventor
Tomas Fex
Bengt Ohlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68425648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020351301(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of AU2020351301A1 publication Critical patent/AU2020351301A1/en
Publication of AU2020351301B2 publication Critical patent/AU2020351301B2/en
Priority to AU2026203399A priority Critical patent/AU2026203399A1/en
Application granted granted Critical
Publication of AU2020351301C1 publication Critical patent/AU2020351301C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020351301A 2019-09-20 2020-09-18 New compounds Active AU2020351301C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026203399A AU2026203399A1 (en) 2019-09-20 2026-05-04 New compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds
GB1913603.5 2019-09-20
PCT/GB2020/052261 WO2021053344A1 (en) 2019-09-20 2020-09-18 New compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026203399A Division AU2026203399A1 (en) 2019-09-20 2026-05-04 New compounds

Publications (3)

Publication Number Publication Date
AU2020351301A1 AU2020351301A1 (en) 2022-03-17
AU2020351301B2 AU2020351301B2 (en) 2026-02-12
AU2020351301C1 true AU2020351301C1 (en) 2026-08-06

Family

ID=68425648

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020351301A Active AU2020351301C1 (en) 2019-09-20 2020-09-18 New compounds
AU2026203399A Pending AU2026203399A1 (en) 2019-09-20 2026-05-04 New compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026203399A Pending AU2026203399A1 (en) 2019-09-20 2026-05-04 New compounds

Country Status (15)

Country Link
US (2) US12435072B2 (cg-RX-API-DMAC7.html)
EP (1) EP4031240A1 (cg-RX-API-DMAC7.html)
JP (2) JP7771049B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220101071A (cg-RX-API-DMAC7.html)
CN (1) CN114786774A (cg-RX-API-DMAC7.html)
AU (2) AU2020351301C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003130A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152218A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000656A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022003091A2 (cg-RX-API-DMAC7.html)
GB (1) GB201913603D0 (cg-RX-API-DMAC7.html)
IL (1) IL291172A (cg-RX-API-DMAC7.html)
MX (2) MX2022003286A (cg-RX-API-DMAC7.html)
PH (1) PH12022550564A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021053344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
JP2024511453A (ja) * 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンii受容体リガンド
GB202113583D0 (en) * 2021-09-23 2021-11-10 Vicore Pharma Ab New compounds
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
CA3222721A1 (en) * 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
WO2023193733A1 (zh) * 2022-04-06 2023-10-12 武汉人福创新药物研发中心有限公司 一种at2r激动剂
WO2024133942A1 (en) 2022-12-22 2024-06-27 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
CN120569378A (zh) * 2023-01-09 2025-08-29 维科尔药物公司 选择性血管紧张素ii化合物
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯
WO2025146172A1 (zh) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 一种并环类化合物作为at2r激动剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096883A1 (en) * 2001-05-31 2002-12-05 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE19920815A1 (de) 1999-05-05 2000-11-09 Aventis Pharma Gmbh 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
JP4707321B2 (ja) 2001-05-31 2011-06-22 ヴィコール・ファルマ・アーベー アンギオテンシンiiアゴニストとして有用な三環式化合物
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) * 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
JP2015504870A (ja) * 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
ES2834430T3 (es) 2013-03-15 2021-06-17 Univ Southern California Procedimientos, compuestos y composiciones para el tratamiento de enfermedades relacionadas con la angiotensina
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
US20170266164A1 (en) 2014-12-12 2017-09-21 Vicore Pharma Ab New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
BR112018077075A2 (pt) 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096883A1 (en) * 2001-05-31 2002-12-05 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIONGYU WU et al., J. MED. CHEM., vol. 49, 2006, pages 7160 - 7168. *

Also Published As

Publication number Publication date
US12435072B2 (en) 2025-10-07
JP7771049B2 (ja) 2025-11-17
US20220388994A1 (en) 2022-12-08
AU2020351301B2 (en) 2026-02-12
MX2022003286A (es) 2022-04-12
CN114786774A (zh) 2022-07-22
AU2020351301A1 (en) 2022-03-17
MX2025000262A (es) 2025-02-10
JP2022549086A (ja) 2022-11-24
KR20220101071A (ko) 2022-07-19
IL291172A (en) 2022-05-01
AU2026203399A1 (en) 2026-05-21
PH12022550564A1 (en) 2023-03-20
EP4031240A1 (en) 2022-07-27
WO2021053344A1 (en) 2021-03-25
BR112022003130A2 (pt) 2022-05-17
CL2022000656A1 (es) 2022-11-04
CO2022003091A2 (es) 2022-04-19
US20260028333A1 (en) 2026-01-29
CA3152218A1 (en) 2021-03-25
JP2026041728A (ja) 2026-03-10
GB201913603D0 (en) 2019-11-06

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 MAY 2026

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 MAY 2026